| abstract |
The present invention relates to substance dependence (e.g., cocaine, amphetamine, methamphetamine, methylphenidate, heroin, codeine, hydrocodone, nicotine, alcohol, prescription drugs (e.g., Percodan (R), Percoset (R)), Marijuana, tobacco, methadone, food), activity addiction (eg gambling, sex, eating), substance use disorders, mood disorders, anxiety disorders, bipolar disorder, sleep disorders, insomnia, post-traumatic stress Syndrome, borderline personality disorder, disruptive behavior disorder, ADHD, major depression disorder, burnout syndrome, chronic fatigue syndrome, fibromyalgia, irritable bowel syndrome, eating disorders (eg, Praderwillie syndrome), obesity, depression , Menopause, premenstrual syndrome (PMS), obsessive compulsive disorder (OCD), social anxiety, generalized anxiety disorder, dysthymia, Such as schizophrenia, for treating disorders associated with abnormal activity in the HPA axis, and wherein the composition comprising a first agent and a second agent. |